MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
30.77
+0.33
+1.08%
Opening 10:01 07/25 EDT
OPEN
30.50
PREV CLOSE
30.44
HIGH
30.96
LOW
30.50
VOLUME
22.01K
TURNOVER
0
52 WEEK HIGH
35.44
52 WEEK LOW
21.99
MARKET CAP
1.69B
P/E (TTM)
-108.1927
1D
5D
1M
3M
1Y
5Y
1D
Third Avenue Small Cap Value Fund Q2 2024 Commentary
Third Avenue Small Cap Value Fund returned -5.98% during the second quarter of 2024, compared to a return of -3.64% for the Russell 2000 Value Index. The Russell 1000 Index has outperformed the small-cap index by 12.50% in the first half of 2024. Amazon.com Inc. Is one of the greatest success stories of our lifetime.
Seeking Alpha · 11m ago
Supernus Pharmaceuticals Currently Up 13 Consecutive Days, on Track for Record Winning Streak -- Data Talk
Dow Jones · 2d ago
Weekly Report: what happened at SUPN last week (0715-0719)?
Weekly Report · 3d ago
Aristotle Capital Small/Mid Cap Equity Q2 2024 Commentary
Seeking Alpha · 07/18 11:40
Weekly Report: what happened at SUPN last week (0708-0712)?
Weekly Report · 07/15 11:14
Supernus Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for SUPN
NASDAQ · 07/11 18:14
Weekly Report: what happened at SUPN last week (0701-0705)?
Weekly Report · 07/08 11:16
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Seeking Alpha · 07/02 11:30
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.